A phase III, randomized, double-blind, multi-center study of the efficacy of Taxotere (docetaxel) in combination with Aptosyn (exisulind) versus Taxotere (docetaxel) and placebo in non-small cell lung cancer (NSCLC) patients after failure of prior platinum-based chemotherapy
Phase of Trial: Phase III
Latest Information Update: 17 Sep 2005
At a glance
- Drugs Docetaxel; Exisulind
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 17 Sep 2005 New trial record.